David Chu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11544504/publications.pdf

Version: 2024-02-01

38 papers	1,743 citations	331538 21 h-index	315616 38 g-index
38 all docs	38 docs citations	38 times ranked	3580 citing authors

#	Article	IF	Citations
1	Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. Clinical Cancer Research, 2014, 20, 2643-2650.	3.2	341
2	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 993-999.	3.2	152
3	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research, 2017, 19, 60.	2.2	116
4	Single Amino Acid Changes in the Nipah and Hendra Virus Attachment Glycoproteins Distinguish EphrinB2 from EphrinB3 Usage. Journal of Virology, 2007, 81, 10804-10814.	1.5	91
5	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clinical Biochemistry, 2015, 48, 993-998.	0.8	91
6	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. Cancer Research, 2018, 78, 1110-1122.	0.4	85
7	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget, 2016, 7, 6281-6293.	0.8	76
8	HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6205-14.	3.3	69
9	Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer, 2016, 122, 3015-3023.	2.0	60
10	A Mechanistic Study of Tumor-Targeted Corrole Toxicity. Molecular Pharmaceutics, 2011, 8, 2233-2243.	2.3	57
11	Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity. Journal of Controlled Release, 2012, 163, 368-373.	4.8	54
12	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 379-386.	3.2	50
13	Cysteines in the Stalk of the Nipah Virus G Glycoprotein Are Located in a Distinct Subdomain Critical for Fusion Activation. Journal of Virology, 2012, 86, 6632-6642.	1.5	49
14	Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. Cancer Research, 2017, 77, 5602-5613.	0.4	48
15	Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 147-154.	1.4	41
16	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. Journal of Clinical Investigation, 2019, 129, 4708-4723.	3.9	41
17	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. Clinical Cancer Research, 2017, 23, 4875-4884.	3.2	35
18	TMSB4Yis a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Oncotarget, 2015, 6, 44927-44940.	0.8	34

#	Article	IF	Citations
19	Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. Endocrinology, 2018, 159, 285-296.	1.4	32
20	Multimodality Imaging In Vivo for Preclinical Assessment of Tumor-Targeted Doxorubicin Nanoparticles. PLoS ONE, 2012, 7, e34463.	1.1	26
21	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-14.	1.5	23
22	NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11583-11588.	3.3	21
23	Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, 2017, 8, 15651-15662.	0.8	20
24	PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Research and Treatment, 2017, 162, 451-464.	1.1	16
25	Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine, 2012, 7, 335-352.	1.7	14
26	A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics, 2015, 15, 318-326.	1.3	13
27	Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Human Pathology, 2014, 45, 1546-1550.	1.1	12
28	A Polycythemia VeraJAK2Mutation Masquerading as a Duodenal Cancer Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1495-1498.	2.3	12
29	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. Journal of Clinical Investigation, 2021, 131, .	3.9	11
30	ERpS294 is a biomarker of ligand or mutational ERÎ± activation and a breast cancer target for CDK2 inhibition. Oncotarget, 2017, 8, 83432-83445.	0.8	11
31	Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. Journal of Controlled Release, 2018, 271, 127-138.	4.8	9
32	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget, 2015, 6, 25240-25251.	0.8	9
33	HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo. Nucleic Acids Research, 2019, 47, 11020-11043.	6.5	7
34	Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR. Clinical Chemistry, 2017, 63, 1370-1376.	1.5	6
35	Investigating the photosensitizer-potential of targeted gallium corrole using multimode optical imaging. Proceedings of SPIE, 2011, 7886, .	0.8	5
36	Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Practical Laboratory Medicine, 2018, 12, e00108.	0.6	3

#	Article	IF	Citations
37	The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. Breast Cancer Research and Treatment, 2019, 174, 401-412.	1.1	2
38	NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. Oncotarget, 2022, 13, 373-386.	0.8	1